Co-organised by Gustave Roussy, the 13rd TAT Congress took place in Paris from the 2nd to the 4th of March. Presided over this year by Prof. Jean-Charles Soria, Head of the Drug Development Department (DITEP) at Gustave Roussy, the TAT congress is the first International Meeting on the early development of medicines in oncology.
Investigators and biotechnology companies had the unique opportunity of meeting and exchanging information with worldwide experts in early clinical research, on new therapeutic targets and on innovative therapies in oncology.
In this years’ programme, a wide range of therapeutic advances was presented during 11 plenary sessions, notably by the investigating physicians from Gustave Roussy, in the forefront of thematics in the field of oncology such as immunotherapy, epigenetics or tumour metabolism.
Notable in this programme is the presentation by Dr. Christophe Massard, a medical oncologist at Gustave Roussy, on the updated results of the MOSCATO trial (MOlecular Screening for Cancer Treatment Optimization). The recent introduction of complete genome sequencing (WES) and of RNA (RNA seq) has yielded interesting preliminary results. This trial, promoted by Gustave Roussy, aims to validate in clinical practice the implementation of high flow analytical techniques in order to obtain the molecular description of the tumour of each patient and thus to refer them for the most suitable targeted therapies in order to validate the concept of “personalised medicine”.